Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols

What Was Tested

This clinical trial paper looks at Parathyroid Hormone (PTH 1-84) in the context of hyperparathyroidism.

Patients with secondary hyperparathyroidism experience a variety of clinical symptoms which may adversely affect physical and mental function.

As part of a multicenter, open-label clinical trial, subjects completed a questionnaire that included the Medical Outcomes Study Short Form-36 and 14 kidney disease-related symptoms at multiple time points during the study.

Who Took Part

The abstract describes 567 subjects taking part.

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a open-label and multicenter study.

Being open-label, the Parathyroid Hormone (PTH 1-84) study did not mask who received what.

More than one site took part, so the subjects came from several places.

What Was Measured

Patients with secondary hyperparathyroidism experience a variety of clinical symptoms which may adversely affect physical and mental function.

As part of a multicenter, open-label clinical trial, subjects completed a questionnaire that included the Medical Outcomes Study Short Form-36 and 14 kidney disease-related symptoms at multiple time points during the study.

Topics PubMed links to this paper include Cinacalcet, Cohort Studies, Hyperparathyroidism, Secondary, Kidney Failure, Chronic, Naphthalenes, Parathyroid Hormone and Quality of Life.

What This Means in Plain Language

The paper is an open-label and multicenter study of Parathyroid Hormone (PTH 1-84) in 567 subjects in people with hyperparathyroidism.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2012 (Hemodialysis international. International Symposium on Home Hemodialysis), a journal based in Canada.

More context: the Parathyroid Hormone (PTH 1-84) compound page, Hyperparathyroidism research.